- Home
- CYH vs ORIC Comparison
CYH vs ORIC Comparison
Compare CYH & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | ORIC |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.4M | 783.0M |
| IPO Year | 1991 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CYH | ORIC |
|---|---|---|
| Price | $3.22 | $8.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $3.73 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 1.8M | 1.5M |
| Earning Date | 02-17-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $12,644,000,000.00 | N/A |
| Revenue This Year | $0.04 | N/A |
| Revenue Next Year | $0.86 | N/A |
| P/E Ratio | $1.30 | ★ N/A |
| Revenue Growth | ★ 0.74 | N/A |
| 52 Week Low | $2.24 | $3.90 |
| 52 Week High | $4.47 | $14.93 |
Technical Indicators
Market Signals| Indicator | CYH | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 27.08 |
| Support Level | $3.16 | $7.98 |
| Resistance Level | $3.34 | $8.44 |
| Average True Range (ATR) | 0.10 | 0.44 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 20.42 | 8.78 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.